@article{c99fdd65d23f4cbea49567549d1d99ad,
title = "Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease",
abstract = "The healing of the intestine is becoming an important objective in the management of inflammatory bowel diseases. It is associated with improved disease outcome. Therefore the assessment of this healing both in clinical studies and routine practice is a key issue. Endoscopy for the colon and terminal ileum and computerized tomography or magnetic resonance imaging for the small bowel are the most direct ways to evaluate intestinal healing. However, there are many unsolved questions about the definition and the precise assessment of intestinal healing using these endoscopic and imaging techniques. Furthermore, these are relatively invasive and expensive procedures that may be inadequate for regular patients' monitoring. Therefore, biomarkers such as C-reactive protein and fecal calprotectin have been proposed as surrogate markers for intestinal healing. Nevertheless, the sensitivity and specificity of these markers for the prediction of healing may be insufficient for routine practice. New stool, blood or intestinal biomarkers are currently studied and may improve our ability to monitor intestinal healing in the future.",
keywords = "Endoscopy, Fecal markers, Genetic markers, Imaging techniques, Inflammatory bowel disease, Mucosal healing, Serologic markers, Transmural healing",
author = "Marco Daperno and Fabiana Castiglione and {de Ridder}, Lissy and Iris Dotan and Martti F{\"a}rkkil{\"a} and Jon Florholmen and Gerald Fraser and Walter Fries and Xavier Hebuterne and Lakatos, {Peter Laszlo} and Juli{\'a}n Pan{\'e}s and Jordi Rimola and Edouard Louis",
note = "Funding Information: MD received consultancy fees from Schering Plough, Abbott, MSD; received lecture fees from Schering Plough, Abbott, MSD, Sofar, Chiesi, Ferring, Nycomed. ID received consultancy fees from Abbott Laboratories, Merck, Bioline, Centocor; research support from Teva, Israel; lecture fees from Ferring, Schering Plough. MF received consultancy fees from Abbott, MSD, Bayer and Roche; received research grants from MSD, Roche; received lecture fees from Abbott, MSD, Bayer and Roche. GF received consultancy fees from Abbott Laboratories-Israel. WF received lecture fees from Schering-Plough, Abbott, Nycomed; research or educational grants from Schering-Plough, Abbott, Giuliani. PLL received consultancy fees from Schering Plough-MSD, Abbott; received research or educational grants from Schering Plough-MSD, Abbott, Astellas; received lecture fees from Schering Plough-MSD, Abbott, Ferring. JP received consultancy fees from Schering Plough, Abbott, MSD, UCB; received research or educational grants from, Schering Plough, Abbott; received lecture fees from Abbott, Ferring, MSD, and Schering Plough. JR received research grants from Abbott. EL received consultancy fees from Schering Plough, Abbott, MSD, Ferring, Shire, Millenium, UCB; received research or educational grants from MSD, Schering Plough, Astra Zeneca, Abbott; received lecture fees from Abbott, Astra Zeneca, Ferring, MSD, Schering Plough, Falk, Menarini, Chiesi, Nycomed. ",
year = "2011",
month = oct,
doi = "10.1016/j.crohns.2011.07.003",
language = "אנגלית",
volume = "5",
pages = "484--498",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Oxford University Press",
number = "5",
}